Broadly neutralizing antibodies targeting a highly conserved region in the hemagglutinin (HA) stem protect against influenza infection. Here, we investigate the protective efficacy of a protein (HB36.6) computationally designed to bind with high affinity to the same region in the HA stem. We show that intranasal delivery of HB36.6 affords protection in mice lethally challenged with diverse strains of influenza independent of Fc-mediated effector functions or a host antiviral immune response. This designed protein prevents infection when given as a single dose of 6.0 mg/kg up to 48 hours before viral challenge and significantly reduces disease when administered as a daily therapeutic after challenge. A single dose of 10.0 mg/kg HB36.6 administered 1-day post-challenge resulted in substantially better protection than 10 doses of oseltamivir administered twice daily for 5 days. Thus, binding of HB36.6 to the influenza HA stem region alone, independent of a host response, is sufficient to reduce viral infection and replication in vivo. These studies demonstrate the potential of computationally designed binding proteins as a new class of antivirals for influenza.
References
[1]
DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med. 2014 Feb 12;20(2):143–51. doi: 10.1038/nm.3443. pmid:24412922
[2]
Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev. 1992 Apr;56(1):152–79. pmid:1579108
[3]
Falcone V, Bierbaum S, Kern W, Kontny U, Bertz H, Huzly D, et al. Influenza virus A(H1N1)pdm09 hemagglutinin polymorphism and associated disease in southern Germany during the 2010/11 influenza season. Arch Virol. 2013 Jul;158(6):1297–303. doi: 10.1007/s00705-013-1610-1. pmid:23397331
[4]
Lambert LC, Fauci AS. Influenza vaccines for the future. N Engl J Med. 2010 Nov 18;363(21):2036–44. doi: 10.1056/NEJMra1002842. pmid:21083388
[5]
Girard MP, Tam JS, Assossou OM, Kieny MP. The 2009 A (H1N1) influenza virus pandemic: A review. Vaccine. 2010 Jul;28(31):4895–902. doi: 10.1016/j.vaccine.2010.05.031. pmid:20553769
[6]
Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, et al. A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins. Science. 2011 Aug 11;333(6044):850–6. doi: 10.1126/science.1205669. pmid:21798894
[7]
Ekiert DC, Wilson IA. Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Curr Opin Virol. 2012 May;2(2):134–41. doi: 10.1016/j.coviro.2012.02.005. pmid:22482710
[8]
Krammer F, Palese P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol. 2013 Oct 01;3(5):521–30. doi: 10.1016/j.coviro.2013.07.007. pmid:23978327
[9]
Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell. 2014 Sep 11;158(6):1243–53. doi: 10.1016/j.cell.2014.08.023. pmid:25215485
[10]
Tharakaraman K, Subramanian V, Cain D, Sasisekharan V, Sasisekharan R. Broadly neutralizing influenza hemagglutinin stem-specific antibody CR8020 targets residues that are prone to escape due to host selection pressure. Cell Host Microbe. 2014 May 14;15(5):644–51. doi: 10.1016/j.chom.2014.04.009. pmid:24832457
[11]
Fleishman SJ, Whitehead TA, Ekiert DC, Dreyfus C, Corn JE, Strauch EM, et al. Computational Design of Proteins Targeting the Conserved Stem Region of Influenza Hemagglutinin. Science. 2011 Jun 12;332(6031):816–21. doi: 10.1126/science.1202617. pmid:21566186
[12]
Whitehead TA, Chevalier A, Song Y, Dreyfus C, Fleishman SJ, De Mattos C, et al. Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing. Nat Biotechnol. 2012 Jun 27;30(6):543–8. doi: 10.1038/nbt.2214. pmid:22634563
[13]
Fowler DM, Araya CL, Gerard W, Fields S. Enrich: software for analysis of protein function by enrichment and depletion of variants. Bioinformatics. 2011 Dec 15;27(24):3430–1. doi: 10.1093/bioinformatics/btr577. pmid:22006916
[14]
De Clercq E. Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015–25. pmid:17139286 doi: 10.1038/nrd2175
[15]
Rowe T, Banner D, Farooqui A, Ng DC, Kelvin AA, Rubino S, et al. In vivo ribavirin activity against severe pandemic H1N1 Influenza A/Mexico/4108/2009. J Gen Virol. 2010 Dec;91(Pt 12):2898–906. doi: 10.1099/vir.0.024323-0. pmid:20797971
[16]
Browne MJ, Moss MY, Boyd MR. Comparative activity of amantadine and ribavirin against influenza virus in vitro: possible clinical relevance. Antimicrob Agents Chemother. 1983 Mar;23(3):503–5. pmid:6847176 doi: 10.1128/aac.23.3.503
[17]
Smee DF, Wong MH, Bailey KW, Sidwell RW. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses. Antivir Chem Chemother. 2006;17(4):185–92. pmid:17066897 doi: 10.1177/095632020601700403
[18]
Ilyushina NA, Khalenkov AM, Seiler JP, Forrest HL, Bovin NV, Marjuki H, et al. Adaptation of pandemic H1N1 influenza viruses in mice. J Virol. 2010 Sep;84(17):8607–16. doi: 10.1128/JVI.00159-10. pmid:20592084
[19]
Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014;4:CD008965. doi: 10.1002/14651858.CD008965.pub4. pmid:24718923
[20]
Sidwell RW, Bailey KW, Bemis PA, Wong MH, Eisenberg EJ, Huffman JH. Influence of treatment schedule and viral challenge dose on the in vivo influenza virus-inhibitory effects of the orally administered neuraminidase inhibitor GS 4104. Antivir Chem Chemother. 1999 Jul;10(4):187–93. pmid:10480737 doi: 10.1177/095632029901000403
[21]
Baranovich T, Burnham AJ, Marathe BM, Armstrong J, Guan Y, Shu Y, et al. The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome. J Infect Dis. 2014 May 1;209(9):1343–53. doi: 10.1093/infdis/jit554. pmid:24133191
[22]
McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev Micro. 2014 May;12(4):252–62. doi: 10.1038/nrmicro3231
[23]
Shrestha S, Foxman B, Weinberger DM, Steiner C, Viboud C, Rohani P. Identifying the Interaction Between Influenza and Pneumococcal Pneumonia Using Incidence Data. Sci Transl Med. 2013 Jul 26;5(191):191ra84–ra84. doi: 10.1126/scitranslmed.3005982. pmid:23803706
[24]
Connaris H, Govorkova EA, Ligertwood Y, Dutia BM, Yang L, Tauber S, et al. Prevention of influenza by targeting host receptors using engineered proteins. P Natl Acad Sci Usa. 2014 May 29;111(17):6401–6. doi: 10.1073/pnas.1404205111
[25]
Ohbo K, Suda T, Hashiyama M, Mantani A, Ikebe M, Miyakawa K, et al. Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma chain. Blood. 1996 Feb 1;87(3):956–67. pmid:8562967
[26]
Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G, et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood. 2005 Sep 1;106(5):1565–73. pmid:15920010 doi: 10.1182/blood-2005-02-0516
[27]
Seo SU, Kwon HJ, Song JH, Byun YH, Seong BL, Kawai T, et al. MyD88 signaling is indispensable for primary influenza A virus infection but dispensable for secondary infection. J Virol. 2010 Dec;84(24):12713–22. doi: 10.1128/JVI.01675-10. pmid:20943980
[28]
Koyama S, Ishii KJ, Kumar H, Tanimoto T, Coban C, Uematsu S, et al. Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J Immunol. 2007 Oct 1;179(7):4711–20. pmid:17878370 doi: 10.4049/jimmunol.179.7.4711
[29]
Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J Exp Med. 2009 Jan 16;206(1):79–87. doi: 10.1084/jem.20081667. pmid:19139171
[30]
Leyva-Grado VH, Tan GS, Leon PE, Yondola M, Palese P. Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies. Antimicrob Agents Chemother. 2015 Jul;59(7):4162–72. doi: 10.1128/AAC.00290-15. pmid:25941218
[31]
Morbidity and Mortality Weekly Report. 2010 Aug 25. Report No.
[32]
Gerlach RL, Camp JV, Chu YK, Jonsson CB. Early host responses of seasonal and pandemic influenza A viruses in primary well-differentiated human lung epithelial cells. PLoS One. 2013;8(11):e78912. doi: 10.1371/journal.pone.0078912. pmid:24244384
[33]
Chen J, Yan B, Chen Q, Yao Y, Wang H, Liu Q, et al. Evaluation of neutralizing efficacy of monoclonal antibodies specific for 2009 pandemic H1N1 influenza A virus in vitro and in vivo. Arch Virol. 2014 Mar;159(3):471–83. doi: 10.1007/s00705-013-1852-y. pmid:24057757
[34]
Walsh KB, Teijaro JR, Wilker PR, Jatzek A, Fremgen DM, Das SC, et al. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc Natl Acad Sci USA. 2011 Jul 19;108(29):12018–23. doi: 10.1073/pnas.1107024108. pmid:21715659
[35]
Zarogiannis SG, Noah JW, Jurkuvenaite A, Steele C, Matalon S, Noah DL. Comparison of ribavirin and oseltamivir in reducing mortality and lung injury in mice infected with mouse adapted A/California/04/2009 (H1N1). Life Sci. 2012 Mar 10;90(11–12):440–5. doi: 10.1016/j.lfs.2011.12.014. pmid:22269828
[36]
Dunning J, Baillie JK, Cao B, Hayden FG, on behalf of the International Severe Acute R, Emerging Infection C. Antiviral combinations for severe influenza. Lancet Infect Dis. 2014 Dec;14(12):1259–70. doi: 10.1016/S1473-3099(14)70821-7. pmid:25213733
[37]
Smee DF, Hurst BL, Wong MH, Bailey KW, Tarbet EB, Morrey JD, et al. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother. 2010 Jan;54(1):126–33. doi: 10.1128/AAC.00933-09. pmid:19901093
[38]
Basu A, Antanasijevic A, Wang M, Li B, Mills DM, Ames JA, et al. New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusion. J Virol. 2014 Feb;88(3):1447–60. doi: 10.1128/JVI.01225-13. pmid:24198411
[39]
Shriver Z, Trevejo JM, Sasisekharan R. Antibody-Based Strategies to Prevent and Treat Influenza. Front Immunol. 2015;6:315. doi: 10.3389/fimmu.2015.00315. pmid:26217334
[40]
Pizzorno A, Abed Y, Boivin G. Influenza drug resistance. Semin Respir Crit Care Med. 2011 Aug;32(4):409–22. doi: 10.1055/s-0031-1283281. pmid:21858746
[41]
Ison MG. Antivirals and resistance: influenza virus. Curr Opin Virol. 2011 Dec;1(6):563–73. doi: 10.1016/j.coviro.2011.09.002. pmid:22440914
[42]
Kunkel TA. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci USA. 1985 Feb;82(2):488–92. pmid:3881765 doi: 10.1073/pnas.82.2.488
[43]
Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD. Isolating and engineering human antibodies using yeast surface display. Nat Protoc. 2006 Jul;1(2):755–68. pmid:17406305 doi: 10.1038/nprot.2006.94
[44]
Araya CL, Fowler DM, Chen W, Muniez I, Kelly JW, Fields S. A fundamental protein property, thermodynamic stability, revealed solely from large-scale measurements of protein function. Proc Natl Acad Sci USA. 2012 Oct 16;109(42):16858–63. doi: 10.1073/pnas.1209751109. pmid:23035249
[45]
Patrick WM, Firth AE, Blackburn JM. User-friendly algorithms for estimating completeness and diversity in randomized protein-encoding libraries. Protein Eng. 2003 Jun;16(6):451–7. pmid:12874379 doi: 10.1093/protein/gzg057
[46]
Hoover DM, Lubkowski J. DNAWorks: an automated method for designing oligonucleotides for PCR-based gene synthesis. Nucleic Acids Res. 2002 May 15;30(10):e43. pmid:12000848 doi: 10.1093/nar/30.10.e43
[47]
Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA 3rd, Smith HO. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods. 2009 May;6(5):343–5. doi: 10.1038/nmeth.1318. pmid:19363495
[48]
Studier FW. Protein production by auto-induction in high density shaking cultures. Protein Expr Purif. 2005 May;41(1):207–34. pmid:15915565 doi: 10.1016/j.pep.2005.01.016
[49]
Choi R, Kelley A, Leibly D, Hewitt SN, Napuli A, Van Voorhis W. Immobilized metal-affinity chromatography protein-recovery screening is predictive of crystallographic structure success. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Sep 1;67(Pt 9):998–1005. doi: 10.1107/S1744309111017374. pmid:21904040
[50]
Bryan CM, Bhandari J, Napuli AJ, Leibly DJ, Choi R, Kelley A, et al. High-throughput protein production and purification at the Seattle Structural Genomics Center for Infectious Disease. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Sep 1;67(Pt 9):1010–4. doi: 10.1107/S1744309111018367. pmid:21904042
[51]
Suloway C, Pulokas J, Fellmann D, Cheng A, Guerra F, Quispe J, et al. Automated molecular microscopy: the new Leginon system. J Struct Biol. 2005 Jul;151(1):41–60. pmid:15890530 doi: 10.1016/j.jsb.2005.03.010
[52]
Lander GC, Stagg SM, Voss NR, Cheng A, Fellmann D, Pulokas J, et al. Appion: an integrated, database-driven pipeline to facilitate EM image processing. J Struct Biol. 2009 Apr;166(1):95–102. pmid:19263523 doi: 10.1016/j.jsb.2009.01.002
[53]
Voss NR, Yoshioka CK, Radermacher M, Potter CS, Carragher B. DoG Picker and TiltPicker: software tools to facilitate particle selection in single particle electron microscopy. J Struct Biol. 2009 May;166(2):205–13. pmid:19374019 doi: 10.1016/j.jsb.2009.01.004
[54]
Sorzano CO, Bilbao-Castro JR, Shkolnisky Y, Alcorlo M, Melero R, Caffarena-Fernandez G, et al. A clustering approach to multireference alignment of single-particle projections in electron microscopy. J Struct Biol. 2010 Aug;171(2):197–206. doi: 10.1016/j.jsb.2010.03.011. pmid:20362059
[55]
Tang G, Peng L, Baldwin PR, Mann DS, Jiang W, Rees I, et al. EMAN2: an extensible image processing suite for electron microscopy. J Struct Biol. 2007 Jan;157(1):38–46. pmid:16859925 doi: 10.1016/j.jsb.2006.05.009
[56]
Ludtke SJ, Baldwin PR, Chiu W. EMAN: semiautomated software for high-resolution single-particle reconstructions. J Struct Biol. 1999 Dec 1;128(1):82–97. pmid:10600563 doi: 10.1006/jsbi.1999.4174
